Cardiopulmonary effects of antimalarial drugs. VII. Coronary vascular effects of pyridoquinolines.
D000241:Adenosine / Q000037:antagonists & inhibitors; D000818:Animals; D000962:Antimalarials / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output; D003326:Coronary Circulation / Q000187:drug effects*; D004285:Dogs; D004562:Electrocardiography; D004987:Ethers / Q000494:pharmacology / Q000627:therapeutic use; D005021:Ethylamines / Q000494:pharmacology / Q000627:therapeutic use; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D008288:Malaria / Q000188:drug therapy; D008297:Male; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D011652:Pulmonary Circulation / Q000187:drug effects; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D011804:Quinolines / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D014655:Vascular Resistance / Q000187:drug effects; D014693:Ventricular Fibrillation / Q000188:drug therapy
D000962:Antimalarials; D004987:Ethers; D005021:Ethylamines; D011725:Pyridines; D011804:Quinolines; D000241:Adenosine